Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6531438 | 0.91 | LMNA (0.39) | CYP1A2CYP2D6LMNA | |
| SCHEMBL1070327 | 0.86 | CYP1A2 (0.45) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL2237701 | 0.84 | CYP1A2 (0.43) | CYP1A2CYP2D6 | |
| SCHEMBL1875191 | 0.80 | CYP1A2 (0.50) | CYP1A2CYP2D6 | |
| SCHEMBL17804532 | 0.79 | CYP1A2 (0.42) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL8624801 | 0.78 | CYP1A2 (0.53) | CYP1A2CYP2D6 | |
| SCHEMBL708799 | 0.78 | CYP1A2 (0.62) | CYP1A2CYP2D6 | |
| SCHEMBL707888 | 0.78 | CYP1A2 (0.62) | CYP1A2CYP2D6 | |
| SCHEMBL706895 | 0.78 | CYP1A2 (0.62) | CYP1A2CYP2D6 | |
| SCHEMBL707889 | 0.78 | CYP1A2 (0.62) | CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190298865-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-03 | — | — | US | disclosed |
| US-20180022827-A1 | ANTIBODIES TO RISPERIDONE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-25 | — | — | US | disclosed |
| US-9850318-B2 | Antibodies to quetiapine haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-26 | — | — | US | disclosed |
| US-20170343569-A1 | ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-30 | — | — | US | disclosed |
| US-9795685-B2 | Haptens of aripiprazole | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-24 | — | — | US | disclosed |
| US-20170298147-A1 | ANTIBODIES TO PALIPERIDONE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | US | disclosed |
| US-20170204198-A1 | Antibodies to Aripiprazole Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-20 | — | — | US | disclosed |
| US-20170129968-A1 | ANTIBODIES TO PALIPERIDONE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-11 | — | — | US | disclosed |
| US-9611332-B2 | Antibodies to aripiprazole haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-04 | — | — | US | disclosed |
| US-20170072061-A1 | HAPTENS OF ARIPIPRAZOLE | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-16 | — | — | US | disclosed |
| US-20140155585-A1 | HAPTENS OF RISPERIDONE AND PALIPERIDONE | ORTHO-CLINICAL DIAGNOSTICS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140057305-A1 | Antibodies to Quetiapine Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057299-A1 | Antibodies to Aripiprazole Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057297-A1 | Antibodies to Paliperidone Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-8642545-B2 | Erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD (CN) | 2014-02-04 | — | — | US | disclosed |
| US-8642545-B2 | Erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD (CN) | 2014-02-04 | — | — | US | disclosed |
| US-8470986-B2 | Method for production of sugar oxazoline derivative | TOHOKU UNIVERSITY (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20110223318-A1 | METHOD FOR INTRODUCING FUNCTIONAL GROUP TO SURFACE OF MATERIAL | KANGNUNG-WONJU NATIONAL UNIVERSITY INDUSTRY ACADEMY COOPERATION GROUP (KR) | 2011-09-15 | — | — | US | disclosed |
| US-20100323949-A1 | ERYTHROPOIETIN MIMETIC PEPTIDE DERIVATIVE AND ITS PHARMACEUTICAL SALTS, THE PREPARATION AND USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2010-12-23 | — | — | US | disclosed |
| US-20100323949-A1 | ERYTHROPOIETIN MIMETIC PEPTIDE DERIVATIVE AND ITS PHARMACEUTICAL SALTS, THE PREPARATION AND USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155585-A1 | HAPTENS OF RISPERIDONE AND PALIPERIDONE | PRLHR, HRH1, OPRL1 | CYP1A2 616/4885CYP2D6 29/4885LMNA 4782/4885 |
| US-20140057305-A1 | Antibodies to Quetiapine Haptens and Use Thereof | HTR4, HTR3C, SLC6A4 | CYP1A2 487/4885CYP2D6 37/4885LMNA 3412/4885 |
| US-20170298147-A1 | ANTIBODIES TO PALIPERIDONE HAPTENS AND USE THEREOF | LY96, OPRL1, HTR3C | CYP1A2 1564/4885CYP2D6 98/4885LMNA 3836/4885 |
| US-20170204198-A1 | Antibodies to Aripiprazole Haptens and Use Thereof | FCER2, HTR4, HTR3C | CYP1A2 353/4885CYP2D6 31/4885LMNA 4409/4885 |
| US-20180022827-A1 | ANTIBODIES TO RISPERIDONE HAPTENS AND USE THEREOF | HTR4, HTR3C, OPRL1 | CYP1A2 669/4885CYP2D6 65/4885LMNA 3181/4885 |
| US-20140057299-A1 | Antibodies to Aripiprazole Haptens and Use Thereof | FCER2, HTR4, HTR3C | CYP1A2 353/4885CYP2D6 31/4885LMNA 4409/4885 |
| US-20100323949-A1 | ERYTHROPOIETIN MIMETIC PEPTIDE DERIVATIVE AND ITS PHARMACEUTICAL SALTS, THE PREPARATION AND USES THEREOF | EPOR, PROKR1, PROKR2 | CYP1A2 4033/4885CYP2D6 3561/4885LMNA 2199/4885 |
| US-20170072061-A1 | HAPTENS OF ARIPIPRAZOLE | HRH2, HRH4, CYP2D6 | CYP1A2 15/4885CYP2D6 3/4885LMNA 4885/4885 |
| US-20140057297-A1 | Antibodies to Paliperidone Haptens and Use Thereof | LY96, OPRL1, HTR3C | CYP1A2 1564/4885CYP2D6 98/4885LMNA 3836/4885 |
| US-20170129968-A1 | ANTIBODIES TO PALIPERIDONE HAPTENS AND USE THEREOF | LY96, OPRL1, HTR3C | CYP1A2 1564/4885CYP2D6 98/4885LMNA 3836/4885 |
| US-20190298865-A1 | RADIO-PHARMACEUTICAL COMPLEXES | FAP, PHPT1, DNPEP | CYP1A2 2586/4885CYP2D6 2282/4885LMNA 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.